JOHNSON JOHN 4
4 · Axogen, Inc. · Filed Dec 10, 2025
Insider Transaction Report
Form 4
Axogen, Inc.AXGN
Johnson John H
Director
Transactions
- Sale
Common Stock
2025-12-08$31.26/sh−11,802$368,931→ 13,141 total - Exercise/Conversion
Common Stock
2025-12-08$6.30/sh+11,891$74,913→ 25,032 total - Sale
Common Stock
2025-12-08$31.22/sh−11,891$371,273→ 13,141 total - Exercise/Conversion
Common Stock
2025-12-09$6.30/sh+8,545$53,834→ 21,686 total - Sale
Common Stock
2025-12-09$29.98/sh−8,545$256,196→ 13,141 total - Sale
Common Stock
2025-12-09$29.98/sh−13,141$393,993→ 0 total - Exercise/Conversion
Stock Option (right to purchase)
2025-12-08−11,891→ 8,545 totalExercise: $6.30Exp: 2033-09-01→ Common Stock (11,891 underlying) - Exercise/Conversion
Stock Option (right to purchase)
2025-12-09−8,545→ 0 totalExercise: $6.30Exp: 2033-09-01→ Common Stock (8,545 underlying)
Footnotes (4)
- [F1]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.98 to $30.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date.